SAN DIEGO, CA--(Marketwired - Apr 24, 2013) - NuVasive, Inc. (
The Tokyo office will be headed by NuVasive's Executive Vice President of Asia Pacific, Takaaki Tanaka. Tanaka-san has been with the Company since 2009, and brings an extensive 20 years of experience in the spine industry.
"NuVasive's formal presence in Tokyo is a testament to our commitment to surgeon customers and their patients in Japan. We look forward to improving patient outcomes with superior clinical results as we further introduce XLIF ® and our comprehensive spine portfolio to the Japanese market," said Takaaki Tanaka.
NuVasive recently completed several of the first eXtreme Lateral Interbody Fusion (XLIF ® ) surgical procedures in key cities and markets as a minimally disruptive option for lumbar spine fusion to patients and surgeons in Japan.
"This marks an exciting moment in NuVasive history," said Alex Lukianov, Chairman and CEO of NuVasive. "I am especially pleased to formally open our Tokyo office. As a company, we bring a wealth of experience in spine, with proprietary innovative procedures like XLIF ® and procedurally integrated solutions. Our initial reception in Japan has been exceptional, and I look forward to working with Tanaka-san and Russell Powers, our Executive Vice President of International, to improve spine surgery in one of the world's largest spine markets."
With eight international offices located in Europe, Australia, and Asia, NuVasive has a presence in over 35 countries to facilitate the proliferation of the Company's Culture of Speed of Innovation and Absolute Responsiveness on a global basis.
About XLIF ® : XLIF ® is a minimally disruptive surgical procedure performed through the side of the body utilizing proprietary neuromonitoring and an integrated portfolio of instruments and specialized implants for treating a range of spinal pathologies.
For NuVasive Press Materials please visit: http://www.nuvasive.com/about-us/newsroom/
About NuVasive NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4 th largest player in the $8.2 billion global spine market. NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS ® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess ® , a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF ® , NuVasive has built an entire spine franchise. With over 80 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness ® .
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor Contact: Stephan Ogilvie VP, Corporate Development & Investor Relations NuVasive, Inc. 201-322-6515 Email Contact Media: Nicole Collins NuVasive, Inc. 858-909-1907 Email Contact
test123 kjk
